Verrica Pharmaceuticals Inc.
VRCA
$6.11
-$0.04-0.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 50.17% | 98.80% | 101.19% | 52.08% | 34.18% |
| Total Depreciation and Amortization | -24.90% | -46.20% | -40.42% | -38.82% | 16.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -67.68% | -37.35% | -59.79% | -43.52% | -20.84% |
| Change in Net Operating Assets | 149.08% | -28.01% | -385.45% | -82.64% | -184.06% |
| Cash from Operations | 71.42% | 213.17% | 38.60% | 36.45% | -10.73% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 103.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -9,527.27% | -1,735.94% | -2,247.46% | -2,500.64% | -1,526.09% |
| Issuance of Common Stock | 17.80% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 84.46% | -- | -- | -- | -89,966.67% |
| Cash from Financing | -65.40% | -903.53% | -549.22% | -513.77% | 146,122.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -61.28% | 163.55% | 16.52% | 18.80% | 258.32% |